

CITATION REPORT

List of articles citing

Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis

DOI: 10.1046/j.1365-2125.2001.01370.x

British Journal of Clinical Pharmacology, 2001, 51, 451-60.

Source: <https://exaly.com/paper-pdf/32952837/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
117	The effects of portal shunts on intestinal cytochrome P450 3A activity. 2002 , 35, 1549-50; author reply 1550-1		33
116	Pharmacokinetics and metabolism of oral midazolam in preterm infants. <i>British Journal of Clinical Pharmacology</i> , 2002 , 53, 390-2	3.8	77
115	Pharmacokinetics in the newborn. 2003 , 55, 667-86		183
114	Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. 2003 , 22, 48-55		29
113	Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo. 2004 , 10, 5940-8		36
112	Role of biokinetics in risk assessment of drugs and chemicals in children. 2004 , 39, 282-309		49
111	Modelling and clinical trials in paediatrics. 2005 , 60, 379-84, 385-90		1
110	Modelling and Clinical Trials in Paediatrics. 2005 , 60, 385-390		
109	Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. 2005 , 33, 1603-7		122
108	Pharmacokinetics of proton pump inhibitors in children. 2005 , 44, 441-66		73
107	Design, synthesis and evaluation of furanocoumarin monomers as inhibitors of CYP3A4. 2006 , 4, 1604-10		30
106	Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. 2006 , 45, 931-56		363
105	Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. 2006 , 23, 387-96		16
104	Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. 2007 , 51, 2668-73		37
103	Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. 2007 , 4, 252-7		146
102	Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. 2007 , 81, 510-6		143
101	Mechanism-based concepts of size and maturity in pharmacokinetics. 2008 , 48, 303-32		774

100	Intestinal metabolism and transport of drugs in children: the effects of age and disease. 2008 , 47, 3-10	60
99	A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. 2009 , 24, 53-75	258
98	Challenges for drug studies in children: CYP3A phenotyping as example. 2009 , 14, 6-15	35
97	Pharmacokinetics and Pharmacology of Drugs Used in Children. 2009 , 89-146	6
96	Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients. 2010 , 2, 291-299	21
95	Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. 2011 , 7, 935-48	56
94	Pharmacology of Pediatric Anesthesia. 2011 , 179-261	12
93	Neonatal pharmacology: extensive interindividual variability despite limited size. 2011 , 16, 170-84	64
92	Improved xenobiotic metabolism and reduced susceptibility to cancer in gluten-sensitive macaques upon introduction of a gluten-free diet. 2011 , 6, e18648	11
91	Influence of CYP3A5 polymorphism on tacrolimus maintenance doses and serum levels after renal transplantation: age dependency and pharmacological interaction with steroids. 2011 , 15, 525-32	34
90	Gene expression profiling of duodenal biopsies discriminates celiac disease mucosa from normal mucosa. 2011 , 69, 530-7	30
89	Microsomal quercetin glucuronidation in rat small intestine depends on age and segment. 2011 , 39, 1406-14	14
88	Basics and dynamics of neonatal and pediatric pharmacology. 2011 , 205, 3-49	21
87	Ontogeny of oral drug absorption processes in children. 2012 , 8, 1293-303	61
86	Intestinal cytochromes P450 regulating the intestinal microbiota and its probiotic profile. 2012 , 23,	23
85	Pediatric pharmacokinetics: human development and drug disposition. 2012 , 59, 1001-16	41
84	Cytostatic drugs in infants: a review on pharmacokinetic data in infants. 2012 , 38, 3-26	19
83	Ontogeny of mammalian metabolizing enzymes in humans and animals used in toxicological studies. 2012 , 42, 323-57	47

82	Extrahepatic Drug-Metabolizing Enzymes and Their Significance. 2012 , 1		3
81	Variability, Uncertainty, and Sensitivity Analysis. 2012 , 161-181		4
80	Appendices. 2012 , 407-421		9
79	Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations. 2013 , 52, 333-45		55
78	Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions. 2013 , 53, 857-65		47
77	A review of the toxicology and pathology of the gastrointestinal tract. 2013 , 29, 321-38		13
76	Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters. 2014 , 42, 1268-74		101
75	Developmental trajectory of intestinal MDR1/ABCB1 mRNA expression in children. <i>British Journal of Clinical Pharmacology</i> , 2014 , 77, 910-2	3.8	16
74	Ontogeny of CYP3A and P-glycoprotein in the liver and the small intestine of the Göttingen minipig: an immunohistochemical evaluation. 2014 , 114, 387-94		22
73	Clinical pharmacology of midazolam in neonates and children: effect of disease-a review. 2014 , 2014, 309342		47
72	Novel role of the serine protease inhibitor elafin in gluten-related disorders. 2014 , 109, 748-56		40
71	Paediatric oral biopharmaceutics: key considerations and current challenges. 2014 , 73, 102-26		92
70	A physiologically based pharmacokinetic model for voriconazole disposition predicts intestinal first-pass metabolism in children. 2014 , 53, 1171-82		47
69	Population Pharmacokinetics of Piperazine in Young Ugandan Children Treated With Dihydroartemisinin-Piperazine for Uncomplicated Malaria. 2015 , 98, 87-95		15
68	Prediction of Voriconazole Non-linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach. 2015 , 54, 567-8		4
67	Theoretical pharmacokinetic drug alterations in pediatric celiac disease. 2015 , 11, 1539-50		1
66	Response to: "Prediction of Voriconazole Non-Linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach". 2015 , 54, 569-72		1
65	Paediatric pharmacokinetics: key considerations. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 395-404	3.8	111

64	Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. 2016 , 56, 266-83		70
63	Age-mediated changes in the gastrointestinal tract. 2016 , 512, 382-395		53
62	Developmental Pharmacology: Impact on Pharmacokinetics and Pharmacodynamics of Drugs. 2016 , 23-44		2
61	Global marine pollutants inhibit P-glycoprotein: Environmental levels, inhibitory effects, and cocrystal structure. 2016 , 2, e1600001		71
60	Applications of Physiologically Based Pharmacokinetic (PBPK) Models for Pediatric Populations. 2016 , 109-125		2
59	Characterizing the Developmental Trajectory of Sirolimus Clearance in Neonates and Infants. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016 , 5, 411-7	4-5	16
58	Literature Review of Gastrointestinal Physiology in the Elderly, in Pediatric Patients, and in Patients with Gastrointestinal Diseases. 2016 , 105, 476-483		39
57	Functional Comparison of Human Colonic Carcinoma Cell Lines and Primary Small Intestinal Epithelial Cells for Investigations of Intestinal Drug Permeability and First-Pass Metabolism. 2016 , 44, 329-35		38
56	Optimization of intestinal microsomal preparation in the rat: A systematic approach to assess the influence of various methodologies on metabolic activity and scaling factors. 2017 , 38, 187-208		13
55	Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies. 2017 , 64, e26470		46
54	Usefulness of PBPK Modeling in Incorporation of Clinical Conditions in Personalized Medicine. 2017 , 106, 2380-2391		39
53	Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions. 2017 , 38, 209-230		45
52	Perspective: 4βhydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A. 2017 , 49, 18-34		33
51	Pediatric Dose Selection and Utility of PBPK in Determining Dose. 2018 , 20, 31		32
50	Development and applications of a physiologically-based model of paediatric oral drug absorption. 2018 , 115, 57-67		35
49	Buprenorphine in Neonatal Abstinence Syndrome. 2018 , 103, 112-119		15
48	First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018 , 7, 374-383	4-5	17
47	All disease begins in the gut: Influence of gastrointestinal disorders and surgery on oral drug performance. 2018 , 548, 408-422		37

46	Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach. 2018 , 35, 182	15
45	Impact of gastrointestinal disease states on oral drug absorption - implications for formulation design - a PEARL review. 2019 , 71, 674-698	33
44	Pharmacokinetics and Pharmacology of Drugs Used in Children. 2019 , 100-176.e45	3
43	Crohn's Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression. 2019 , 16, 4059-4064	8
42	Population pharmacokinetics of sildenafil in extremely premature infants. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2824-2837	3.8 15
41	Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System. 2019 , 11,	20
40	Pediatric Formulations: Knowledge Gaps Limiting the Expedited Preclinical to Clinical Translation in Children. 2019 , 20, 73	4
39	How to Conduct Clinical Trials in Children: A Tutorial. 2019 , 12, 218-230	11
38	Mind the Gaps: Ontogeny of Human Brain P-gp and Its Impact on Drug Toxicity. 2019 , 21, 67	9
37	The nested enzyme-within-enterocyte (NEWE) turnover model for predicting dynamic drug and disease effects on the gut wall. 2019 , 131, 195-207	5
36	Pediatric Dosing Considerations for Medical Cannabis. 2019 ,	3
35	Physiology of the Neonatal Gastrointestinal System Relevant to the Disposition of Orally Administered Medications. 2019 , 47, 296-313	25
34	Human microbiota in aging and infection: A review. 2019 , 59, 537-545	16
33	A Preterm Physiologically Based Pharmacokinetic Model. Part I: Physiological Parameters and Model Building. 2020 , 59, 485-500	18
32	Pharmacokinetics in children with chronic kidney disease. 2020 , 35, 1153-1172	2
31	Low Bioavailability of Oral Tacrolimus Suspension in Pediatric Kidney Transplant Patients. 2020 , 59, 1483-1485	0
30	Pharmacokinetics in Patients with Cystic Fibrosis: A Systematic Review of Data Published Between 1999 and 2019. 2020 , 59, 1551-1573	6
29	Utility of Quantitative Proteomics for Enhancing the Predictive Ability of Physiologically Based Pharmacokinetic Models Across Disease States. 2020 , 60 Suppl 1, S17-S35	6

28	Impact of gastrointestinal physiology on drug absorption in special populations--An UNGAP review. 2020 , 147, 105280		63
27	Physiologically-based pharmacokinetic models for children: Starting to reach maturation?. 2020 , 211, 107541		38
26	The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study. 2021 , 109, 140-149		7
25	Potential implications of DMET ontogeny on the disposition of commonly prescribed drugs in neonatal and pediatric intensive care units. 2021 , 17, 273-289		0
24	Recent advances in the ontogeny of drug disposition. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	3
23	CFTR Modulators: Does One Dose Fit All?. 2021 , 11,		1
22	Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population. 2021 , 49, 844-855		1
21	Paradoxical Reactions to Midazolam in a Term Parturient After Intravenous Sedation During Cesarean Section. 2021 , 13, e17678		
20	Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy. 2021 , 110, 1547-1557		4
19	Ontogeny of Small Intestinal Drug Transporters and Metabolizing Enzymes Based on Targeted Quantitative Proteomics. 2021 , 49, 1038-1046		3
18	Development of Microbiota - Is the Process Continuing Through Adolescence?. 2022 , 59-59		0
17	Ontogeny of Drug-Metabolizing Enzymes. <i>Methods in Molecular Biology</i> , 2021 , 2342, 551-593	1.4	0
16	Developmental Changes in the Processes Governing Oral Drug Absorption. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014 , 25-42	0.5	5
15	Paediatric Development: Gastrointestinal. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014 , 43-54	0.5	1
14	General Considerations for Pediatric Oral Drug Formulation. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014 , 89-104	0.5	3
13	Typical and Atypical Enzyme Kinetics. 2003 , 211-254		19
12	APPENDICES. 2021 , 567-577		
11	UNCERTAINTY AND POPULATION VARIABILITY. 2021 , 263-292		

10 The Effect of Age on Drug Metabolism. **2006**, 87-96

9 Chapter 24. Pediatric Pharmacokinetics. **2009**,

8 The Interplay Between Drug Release and Intestinal Gut-Wall Metabolism. **2022**, 65-86

7 Special Populations. **2022**, 205-237

6 Altered intravenous drug disposition in people living with cystic fibrosis: a meta-analysis integrating top-down and bottom-up data. *CPT: Pharmacometrics and Systems Pharmacology*, 4-5

5 Cytochrome P450 enzymes in the pediatric population: Connecting knowledge on P450 expression with pediatric pharmacokinetics. **2022**, 365-391 ○

4 Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug. ○

3 Impact of Duodenal Pathology on Oral Drug Bioavailability and Disease Outcomes in Pediatric Crohn's Disease. **2023**, 16, 373 ○

2 Developmental Pharmacokinetics of Antibiotics Used in Neonatal ICU: Focus on Preterm Infants. **2023**, 11, 940 ○

1 Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in Children. ○